Glucagon like Peptide 1 News and Research

RSS

Carb conundrum: debunking the link between pasta and obesity

Researchers reviewed existing data on the impact of diet patterns with high pasta content on body weight.

13 Jun 2023

How does tirzepatide stimulate insulin secretion?

Tirzepatide, a drug approved for diabetes and on the fast track for approval as a weight loss therapy, works through a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy balance, Duke Health researchers report.

6 Jun 2023

Multicenter, 1-year-long real-world study shows effectiveness of semaglutide for weight loss

New research presented at this year's European Congress on Obesity (ECO2023, Dublin, 17-20 May) shows that the obesity drug semaglutide is effective for weight loss in a multicentre, 1-year-long real-world study.

22 May 2023

Tirzepatide improves body composition across a range of adult age groups, study shows

A new analysis of SURMOUNT-1, the first Phase 3 study of tirzepatide in adults for chronic weight management shows that tirzepatide improves body composition across a range of adult age groups.

19 May 2023

Cardiovascular risk reduction in type 2 diabetes: Study urges better use of life-saving therapies

Researchers explore the efficacy of current approaches to reduce the risk of cardiovascular events in patients with type 2 diabetes.

10 May 2023

Boosting gut health with short-chain fatty acids

Research paper provides an overview of short-chain fatty acids (SCFAs) and their role in regulating gut homeostasis. It also discusses SCFA-producing bacteria and potential therapeutic approaches to boost SCFA levels in the gut to treat related diseases.

9 May 2023

Insights from experts on the neurobiological processes involved in appetite regulation

Researchers summarized the main findings related to the neurobiological regulation of appetite presented at the 23rd Harvard Nutrition Obesity Symposium in June 2022.

8 May 2023

Experimental anti-obesity drug may control appetite without surgery or nausea

Imagine getting the benefits of gastric bypass surgery without going under the knife -; a new class of compounds could do just that. In lab animals, these potential treatments reduce weight dramatically and lower blood glucose.

29 Mar 2023

Long-acting GIPRA inhibits feeding and lowers body weight in mice with diet-induced obesity

The hormone glucose-dependent insulinotropic polypeptide (GIP) is considered obesogenic. In contrast, GIP receptor agonists (GIPRAs) have shown reduced feeding and body weight in an obese mouse model. Therefore, the precise effects exerted by GIP and GIPRAs remain elusive.

14 Mar 2023

Hypothalamic inflammation and obesity, study suggests a pathological mechanism

In a recent review published in the European Journal of Endocrinology, researchers discussed current research on the relationship between human obesity and inflammation of the hypothalamus.

14 Mar 2023

Statin-related residual inflammation predicts cardiovascular events and mortality

A recent Lancet study assessed the importance of low-density lipoprotein cholesterol (LDLC) and high-sensitivity C-reactive protein (CRP) as risk predictors of cardiovascular death, cardiovascular events, and all-cause death among patients subjected to statins.

7 Mar 2023

Coordinated, multifaceted intervention can improve preventive care for diabetes, heart disease

A multifaceted intervention to improve prescribing practices increased the likelihood that patients with Type 2 diabetes and heart disease would be prescribed three classes of guideline-recommended medications by more than fourfold, according to research being presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.

6 Mar 2023

Are SGLT2 inhibitors the next blockbuster drug?

Recent clinical trials investigating the therapeutic potency of sodium-glucose cotransporter 2 inhibitors (SGLT2i) have highlighted that this drug is highly effective in treating patients with cardiovascular and renal diseases.

19 Feb 2023

Study provides a rare view of real-world use of off-label drugs prescribed for Type 1 diabetes

Two classes of drugs prescribed off-label for some patients with Type 1 diabetes can provide significant benefits but also come with health concerns, according to a study by UT Southwestern Medical Center researchers.

16 Feb 2023

Preventing, diagnosing, and treating cardiovascular disease in women

An article published in the journal Medical Clinics of North America provides recent updates on cardiovascular disease prevention, diagnosis, and treatment in women.

8 Feb 2023

Weekly weight loss drug reduces BMI in teens

Researchers report that a weekly dose of semaglutide led to a significant BMI reduction in adolescents.

3 Nov 2022

International group of honorees to provide latest insights into preventing and treating obesity

An international group of honorees have been selected to present innovative research designs providing the latest insights into preventing and treating obesity during the 10th annual Obesity Journal Symposium.

14 Oct 2022

Metformin reduces risk of severe COVID-19 in diabetic patients

A new study determines whether antidiabetic agents can reduce complications in COVID-19 patients with diabetes.

10 Oct 2022

Obese children who recently lost weight more likely to show hunger-related brain activity after a meal

Children with obesity, who have recently lost weight, are more likely to show hunger-related activity in their brains after a meal, according to research presented today at the 60th Annual European Society for Paediatric Endocrinology Meeting.

15 Sep 2022

Is there a right time for eating?

In a recent study published in the journal Cell Metabolism, researchers assessed how calorie or energy intake (EI) time influences calorie distribution and all energy expenditure (EE) components, which, in turn, impact energy balance and weight loss in healthy obese people.

12 Sep 2022